Buhl-Jensen P - Search Results

1

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).

Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Buhl-Jensen P, Molife R, Brown R, de Bono JS, Evans TR. Steele NL, et al. Among authors: buhl jensen p. Cancer Chemother Pharmacol. 2011 Jun;67(6):1273-9. doi: 10.1007/s00280-010-1419-5. Epub 2010 Aug 13. Cancer Chemother Pharmacol. 2011. PMID: 20706839 Clinical Trial.

2

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.

Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, Sinha R, Penson RT, Buhl-Jensen P, Crowley E, Tjornelund J, Knoblauch P, de Bono JS. Lassen U, et al. Among authors: buhl jensen p. Br J Cancer. 2010 Jun 29;103(1):12-7. doi: 10.1038/sj.bjc.6605726. Epub 2010 Jun 15. Br J Cancer. 2010. PMID: 20588278 Free PMC article. Clinical Trial.

3

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.

Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS. Steele NL, et al. Among authors: buhl jensen p. Clin Cancer Res. 2008 Feb 1;14(3):804-10. doi: 10.1158/1078-0432.CCR-07-1786. Clin Cancer Res. 2008. PMID: 18245542 Clinical Trial.

4

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.

Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P. Gimsing P, et al. Among authors: buhl jensen p. Eur J Haematol. 2008 Sep;81(3):170-6. doi: 10.1111/j.1600-0609.2008.01102.x. Epub 2008 May 27. Eur J Haematol. 2008. PMID: 18510700 Clinical Trial.

5

Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines.

Dejligbjerg M, Grauslund M, Christensen IJ, Tjørnelund J, Buhl Jensen P, Sehested M. Dejligbjerg M, et al. Among authors: buhl jensen p. Cancer Biomark. 2008;4(2):101-9. doi: 10.3233/cbm-2008-4206. Cancer Biomark. 2008. PMID: 18503161

6

Freeze-fracture study of plasma membranes in wild type and daunorubicin-resistant Ehrlich ascites tumor and P388 leukemia cells.

Sehested M, Simpson D, Skovsgaard T, Buhl-Jensen P. Sehested M, et al. Among authors: buhl jensen p. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(5):327-35. doi: 10.1007/BF02890034. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989. PMID: 2565630

7

Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.

Rømer MU, Kirkebjerg Due A, Knud Larsen J, Hofland KF, Christensen IJ, Buhl-Jensen P, Almholt K, Lerberg Nielsen O, Brünner N, Lademann U. Rømer MU, et al. Among authors: buhl jensen p. Thromb Haemost. 2005 Oct;94(4):859-66. Thromb Haemost. 2005. PMID: 16270643

8

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx^®): a placebo-controlled randomised phase II study (PLIANT).

Glimelius B, Manojlovic N, Pfeiffer P, Mosidze B, Kurteva G, Karlberg M, Mahalingam D, Buhl Jensen P, Kowalski J, Bengtson M, Nittve M, Näsström J. Glimelius B, et al. Among authors: buhl jensen p. Acta Oncol. 2018 Mar;57(3):393-402. doi: 10.1080/0284186X.2017.1398836. Epub 2017 Nov 15. Acta Oncol. 2018. PMID: 29140155 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page